Specialists are questioning the feasibility of three U.S. factories being built to rapidly turn out drugs needed after an attack or disaster, Nature reports.
Certain analysts argued that few useful antidotes are currently available for responding to the types of biological and chemical events envisioned by the production facilities under preparation in Texas, North Carolina and Maryland, the journal reported on Tuesday. Observers also cast doubt on the utility of next-generation smallpox vaccines, as well as other drugs that may be produced at the so-called Centers for Innovation in Advanced Development and Manufacturing.
The United States is relatively unlikely to face a chemical or biological strike for which the factories would prove useful, argued Richard Ebright, a molecular biologist with Rutgers University. The Texas plant is slated to begin generating its first vaccine in the middle of this year, and federal officials plan in the next quarter-century to spend up to $2 billion on medical treatments from that single facility.
Philip Russell, a former biodefense adviser for the George W. Bush administration, suggested the United States should have built just one such production site for civilian and military needs, in line with a 2008 recommendation by the Pentagon’s Defense Advanced Research Projects Agency.
“Rather than one good operation that meets the government’s needs, we got three operations that spread the money around,” Russell said of the $440 million initiative, launched in 2012 by the Health and Human Services Department.
The current plan’s backers, meanwhile, argued that operating several manufacturing plants would provide a fallback if one is compromised by a strike or release of hazardous material.
In addition to the three sites overseen by Health and Human Services, the Defense Department is constructing a $136 million factory in Florida to generate smaller quantities of biodefense products for armed-forces use. That site is expected to operate at an annual cost of $20 million following its scheduled launch in 2015.
What We're Following See More »
"American spies collected information last summer revealing that senior Russian intelligence and political officials were discussing how to exert influence over Donald J. Trump through his advisers." The conversations centered around Paul Manafort, who was campaign chairman at the time, and Michael Flynn, former national security adviser and then a close campaign surrogate. Both men have been tied heavily with Russia and Flynn is currently at the center of the FBI investigation into possible collusion between the Trump campaign and Russia.
"Former FBI Director Robert Mueller has been cleared by U.S. Department of Justice ethics experts to oversee an investigation into possible collusion between then-candidate Donald Trump's 2016 election campaign and Russia." Some had speculated that the White House would use "an ethics rule limiting government attorneys from investigating people their former law firm represented" to trip up Mueller's appointment. Jared Kushner is a client of Mueller's firm, WilmerHale. "Although Mueller has now been cleared by the Justice Department, the White House may still use his former law firm's connection to Manafort and Kushner to undermine the findings of his investigation, according to two sources close to the White House."
Senate Intelligence Committee chairman Richard Burr (R-NC) and ranking member Mark Warner (D-VA) will subpoena two businesses owned by former National Security Advisor Michael Flynn. Burr said, "We would like to hear from General Flynn. We'd like to see his documents. We'd like him to tell his story because he publicly said he had a story to tell."